Nanowear has entered into an exclusive, worldwide supply-chain partnership agreement with Secant Group for scaled manufacturing and production of its medical-grade, cloth-based nanosensor technology.
A year ago, Nanowear acquired FDA approval of its proprietary cloth-based remote cardiac monitoring technology. The Secant Group will help meet Nanowear’s production goals by providing the necessary design, development and manufacturing of medical device components, specifically biomedical textiles, in an ISO 13485-certified facility.
Secant’s sister company, SanaVita Medical, is expected to provide finishing and assembly, packaging and labeling, and regulatory registration and compliance as an FDA-registered facility.
Additionally, Nanowear has continued pre-commercialization development of its undergarment and alert analytics product in congestive heart failure management. Secant Group’s manufacturing capabilities promise to help scale the product’s inventory, in anticipation of Nanowear’s clinical trial in 2018.
“We now have the opportunity to effect high-volume sensor and analytic applications not only in diagnostic and disease management verticals but also in military, industrial safety, automotive, clinical research and beyond,” said Nanowear co-founder and CEO Venk Varadan.
Nanowear develops patented, textile-based nanosensor technology with applications in the cardiac, neurological, industrial safety/government, and sports medicine/performance diagnostics monitoring markets.
Secant Group partners with OEMs to design, develop, and manufacture implantable structures for medical devices that improve quality of life for patients.
SanaVita’s expertise in advanced biomaterials and textile engineering supports its clients efforts to solve complex technical challenges and provide unique solutions that improve patient outcomes.